<DOC>
	<DOC>NCT00134303</DOC>
	<brief_summary>This is a comparison of metformin versus placebo in NASH patients receiving bariatric surgery for obesity.</brief_summary>
	<brief_title>Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity</brief_title>
	<detailed_description>In patients receiving bariatric surgery, a preoperative liver biopsy will confirm the presence of NASH. Those patients with NASH (histologically defined according the Brunt's criteria) will be randomized to receive metformin (2 times 850 mg orally daily) or placebo for a time period of 1 year. A control liver biopsy will be performed after one year.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients receiving bariatric surgery for obesity Other causes of liver disease (hepatitis B virus [HBV], hepatitis C virus [HCV], primary biliary cirrhosis [PBC], etc.) Patients with diabetes type I Patients with endocrinological reasons for obesity (eg. Cushing, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>